HIV vaccine research is a multifaceted endeavor that requires collaboration across many disciplines to develop a vaccine that protects people from HIV infection. The graphic outlines the different areas of research that are being pursued, including vaccine platforms, immune system research, clinical research capacity, and community engagement.
Excerpted From Lab to Jab.
AVAC is excited to launch From the Lab to the Jab, a new series of advocates’ guides that highlight key advocacy issues to ensure equitable access to safe, effective, and affordable vaccines.
Co-created as part of our USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR), with additional support from the New Venture Fund, From the Lab to the Jab issue briefs provide a roadmap for advocacy to advance the development and delivery of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines.
Go to avac.org/FromLabToJab to learn about next generation vaccine research and development; the basics of mRNA technology; initiatives that support local manufacturing; and understanding and overcoming barriers that undermine equitable access to vaccines. Each brief also highlights the advocacy needed to keep these efforts on track and in line with what communities need and want.
Stay tuned for an invitation to join the From the Lab to the Jab Webinar in January 2024, and be part of the conversation that will use these briefs to strengthen advocacy and create a roadmap to achieve key transformational priorities in global health.
This issue brief on the vaccine research and development (R&D) process is one of a series of four briefs, which provide a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines. Additional topics cover the role of mRNA technology, the need for local vaccine production, and issues around global access.
This issue brief covers the web of issues that influence access to vaccines. It is one of a series of four issue briefs, which provide a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines. Additional topics cover the research and development (R&D) process, the role of mRNA technology; and the need for local vaccine production.
A graphic showing the duration between discovery of the microbiologic cause of selected infectious diseases and the development of a vaccine.
Excerpted From the Lab to Jab.
This issue brief on mRNA technology covers what it is, how it works, current knowledge gaps and ideas for advocacy to harness its potential. It is one of a series of four issue briefs, which provide a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines. Additional topics cover the research and development (R&D) process, the need for local vaccine production, and issues around global access.
This issue brief on local vaccine production covers the current state of local production, what is needed to facilitate it, and ideas for advocacy to harness its potential. It is one of four briefs in a series providing a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, TB and
other global public health threats, including approaches to ensure equitable access to these life-saving vaccines once developed. Additional topics cover the research and development (R & D) process, issues around global access; and the advent of the mRNA platform for vaccines.
This dynamic, workshop-style showcase was the first of a series that featured multimedia presentations that took participants through key PrEP resources including: A toolkit to ensure programs related to sexual and reproductive health (SRH) and HIV prevention are well designed to reach and support adolescent girls and young women. Comprehensive databases for tracking PrEP uptake, Implementation research and other critical data by product, country, and population.
Small groups had opportunities to take deep dives into each of the above resources, and explore how they might use these in their work. Additionally, participants provided input on what resources are still needed, collaborate on how to improve and disseminate what exists, and support the development of evidence and networks to advance HIV prevention.
Global PrEP Tracker video / Integrated Study Dashboard video / Breaking the Cycle Toolkit video
Today, on Transgender Day of Remembrance (TDOR), as communities across the globe memorialize trans and gender nonconforming (TGNC) people targeted by violence and state-sanctioned bigotry, AVAC honors the trans community—those lost and those among us. We are committed, now more than ever, to fight these ongoing injustices and support TGNC advocates to lead on issues facing their communities.
Riding the momentum of the release of the No Data No More Manifesto and the Trans-Inclusivity Scorecard, AVAC is relaunching TG ROAR, a program from our larger PxROAR initiative, dedicated to supporting TGNC HIV advocates in Eastern and Southern Africa. The new eight-member cohort will campaign for trans-centered, HIV research and service delivery while addressing the social, political and economic barriers that all too often stand in the way.
Crimes against TGNC are on the rise as are rates of HIV incidence in trans populations. TGNC face unique barriers to testing, adherence to pre-exposure prophylaxis (PrEP) and maintaining viral suppression. Without meaningful trans inclusion in advocacy efforts there will be no epidemic control.
Learn more about AVAC’s new cohort of TG ROAR advocates here:
We continue to fight for transgender rights and invest in TGNC leadership to create a more equitable and just future for all.
Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board hosted a webinar on November 15 to review the current state of HIV cure research. This webinar explored what makes curing HIV so challenging, the strategies being pursued, and what is happening in locally in NYC!